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Abstract 
American cranberry (Vacciniumm macrocarpon) has been long known for its benefits in 
maintaining urinary tract health. Clinical trials have shown that drinking cranberry juice can 
prevent urinary tract infections (UTIs) in various subpopulations that are prone to UTIs, 
especially women, but the mechanisms by which cranberry acts against uropathogenic bacteria 
are still unclear. Studies showed that when exposed to cranberry juice or A-PACs, a group of 
tannins that are unique to cranberry, the adhesion activity and biofilm formation of 
uropathogenic bacteria were reduced. However, the metabolism of cranberry juice has not be 
elucidated, therefore further study is needed to find out whether the anti-bacterial components in 
cranberry could survive the digestive system and reach the urinary tract, and how the 
components or metabolites remaining in urine act against uropathogenic bacteria. We used 
atomic force microscopy (AFM) to study the surface adhesion force of uropathogenic E. coli 
incubated with urine samples that were collected from volunteers after  drinking 16 oz. of 
cranberry juice cocktail (CJC) or water. The urine samples were collected at 0, 2, 4, 6, and 8 
hours after CJC or water consumption. When incubated with post-water urine, the adhesion 
forces of pathogenic bacteria that have fimbriae (E. coli B37, B73, B78, BF1023, CFT 073, and 
J96) did not change; whereas the adhesion forces of these strains decreased over the 8 hour 
period after CJC consumption. The control strain that does not have frimbriae, E. coli HB101, 
showed low adhesion force when incubated with post-water and post-CJC urine. In a human red 
blood cell agglutination (HRBC) assay, the attachment of pathogenic E. coli to red blood cells 
was significantly lower after exposed to post-CJC urine, compared to those exposed to post-
water urine. These results indicate the anti-bacteria components or metabolites of CJC stay active 
in urine, and these compounds prevent adhesion of E. coli by reducing fimbriae-mediated 
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adhesion. We also examined the effects of drinking CJC on biofilm formation of uropathogenic 
bacteria. Female volunteers were given 16 oz. of CJC or placebo, and their urine was collected at 
0, 2, 8, 24, and 48 hours after consumption. Bacteria (E. coli B37, CFT073, BF1023, HB101, and 
S. aureus ATCC43866) were cultured in a mixture of urine and growth media in 96 well 
microtiters. The biofilm formed was quantified by staining the biofilm dissolved in a solvent 
with crystal violet and measuring the absorbance at 600 nm. The results showed that bio film 
formation was reduced within 24 hours after CJC consumption, and it started to increase after 48 
hours, possibly due to the washout of CJC in the system. These studies suggest that CJC can be 
an effective preventive measure for UTIs as it inhibits adhesion and biofilm formation of 
uropathogenic bacteria.  
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Chapter 1: Background 
1.1 Urinary Tract Infections (UTIs) 
1.1.1 Overview 
Following respiratory tract infections, urinary tract infections (UTIs) are the second most 
frequent infections in human body [2]. Defined by a certain threshold number of bacteria in the 
urine (normally 104 to 105 CFU per ml [2]), UTIs consist of urethritis, cystitis, uretheral 
syndrome, and pyelonephritis. Most UTIs develop in an ascending pattern (Figure 1.1), in which 
uropathogenic organisms first colonize in periurethral tissues and pass through the urethra, reach 
the bladder and in some cases continue progressing upward to infect the ureters and eventually 
the kidneys [3].  
 
Figure 2.1 The ascending pattern of UTIs 
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UTIs occurring in an ascending pattern are mostly caused by Gram-negative bacteria 
such as Escherichia coli and Staphylococcus saprophyticus, whereas the much less frequent 
descending UTIs are mostly caused by Gram-positive bacteria such as group B Streptococcus [4]. 
Clinically, UTIs are commonly categorized as uncomplicated and complicated UTIs.  
Complicated UTIs refer to the infections associated with conditions that raise the risk of the 
treatment failure, such as anatomic or functional abnormalities of the urinary tract, the presence 
of foreign bodies (in many cases catheters), multi-antibiotic resistant pathogens, and 
immunosuppression. Most of the acute UTI cases in pre-menopausal women that do not have 
these conditions are uncomplicated [5]. Men are significantly less susceptible to UTIs compared 
to women due to the difference in the structure of male urinary tract, and complicated UTI cases 
are very rare in young men. Subpopulations with a higher risk to UTIs include infants [6], 
women [7], the elderly having medical conditions that induce complicated UTIs [8], patients 
with spinal cord injury and/or catheters [9], patients of acquired immunodeficiency disease 
syndrome [10], and patients of diabetes [11].  
1.1.2 Statistics 
As the most susceptible sub-population to uncomplicated UTIs, 1 in 3 women will have 
at least one UTI by the age of 24 which requires antibiotic treatment, and 40% to 50% of women 
will have at least one UTI in their lifetime [1].  The risk of UTIs in women increases with age 
(Figure 1.2), and women above 70 years old are most prone to UTIs [12]. An estimated 11.3 
million women in the U.S. are diagnosed with UTIs and treated with antibiotics each year, and 
the yearly cost of UTIs is estimated to be $1.6 billion [13]. As a result of medical condition, and 
instrumentation, most commonly catheterization, there is an increased risk of UTIs during 
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hospitalization. According to a report in 2007, UTIs account for 36% of nosocomial infections, 
being the most common nosocomial infections followed by surgical site infections [14].  
 
Figure 1.2 Cumulative probability of physician diagnosed UTIs by age among U.S. women. 
[1]. 
1.1.3 Treatments and problems 
In hospital care, a multiple antibiotic treatment protocol is usually used to treat UTIs [15]. 
In the U.S., the Trimethoprim-Sulphamethoxazole (TMP-SMX) is considered the standard 
antibiotic treatment for UTIs; the treatment guidelines vary in countries, depending on many 
factors such as antibiotic prescription history, population susceptibility [15]. 
As a result of extensive antibiotic use to treat UTIs, urinary pathogens are inevitably 
becoming resistant to beta lactams and even TMP-SMX. Fluoroquinolones have been used as a 
replacement of TMP-SMX, but resistance to this group of antibiotics is increasing too. Some 
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physicians have returned to old antibiotics such as Nitrofurantoin and Fosfomycin because 
resistance to these drugs has stayed low, although these antibiotics either do not reach an ideal 
serum concentration within a short time or have a limited uropathogen spectrum [16]. Antibiotic 
resistance is an increasingly serious problem in treatment of UTIs particularly because women 
are prone to recurrent UTIs once they have their first UTI episode [13], and repeatedly treatment 
using antibiotics leads to development of resistance.  
1.2 Uropathogenic Bacteria and Virulence Factors 
An international survey on the prevalence and antimicrobial resistance of UTI pathogens 
revealed that over 80% of UTIs are caused by Escherichia coli, followed by the second common 
urinary pathogen Staphylococcus saprophyticus, accounting for 10-15% UTIs. Other pathogens 
include Klebsiella, Enterobacter, Enterococci and Proteus species [17]. Many uropathogenic E. 
coli are resistant to frequently prescribed antibiotics including ampicillin, Trimethoprim, 
Sulphamethoxazole, TMP-SMX, and nalidic acid, whereas the antibiotic resistance is less severe 
in other uropathogens [18].  
As the most prevalent uropathogen, E. coli has been intensively studied for its virulence 
factors. Similar to many pathogenic microorganisms, uropathogenic E. coli initiate infection by 
adhering to host tissues, in most cases the urinary tract lining [19]. By attaching to the epithelial 
cells lining the urinary tract, E. coli cells avoid being swept away by urine flow, therefore are 
able to colonize the urinary mucosa and cause infections. Although many pathogens are found to 
adhere to human erythrocytes, the adherence is usually inhibited in the presence of mannose, 
whereas the adherence of E. coli to uroepithelial cells is typically resistant to mannose, often 
referred to as mannose resistant hemagglutination (MRHA) [20]. The association of MRHA with 
E. coli adhesion to epithelial cells is a result of the involvement of fimbriae in both cases [21, 22].  
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E. coli fimbriae could be roughly categorized as type 1, type P, and X fimbriae. Type 1 
fimbriae exist in many E. coli strains, and they demonstrate mannose-sensitive hemagglutination. 
Hemagglutination of type P fimbriae and a group of other less commo n fimbriae named X 
fimbriae is mannose resistant, and strains with these fimbriae are often associated with 
pyelonephritis [19]. P fimbriae are name after the P  blood type antigens they bind to, which are a 
family of oligosaccharides containing a terminal or internal Galα(14)Galβ moiety. The Gal-
Gal moiety is the receptor for P fimbriae. P-fimbriated E. coli are mostly associated with acute 
pyelonephritis, less with cystitis and rare with asymptomatic bacteriuria [23, 24]. The X fimbriae 
bind to urinary tract lining at various locations and cause infections in both upper and lower 
urinary tract. This family of fimbriae consists of several subgroups that have structures distinct 
from P fimbriae including some unidentified fimbriae, and the binding mechanisms of X 
fimbriae are not thoroughly understood. 
1.3 Cranberry and UTIs 
1.3.1 Overview 
American cranberry (Vaccinium macrocarpon) is a member of the North American fruit 
family. The fruit of cranberry is widely consumed in a variety of food products such as juices, 
fruits, dried fruits, sauces and tablets. It has been long known that cranberry juice is beneficial in 
maintaining urinary tract health, reports that relate cranberry to urinary tract health trace back to 
the early 1900s [25]. Ever since 1966 when the first clinical trial was conducted to study 
cranberry’s effects on UTIs [26], about a dozen of clinical studies have been performed to 
evaluate cranberry’s effect on various subpopulations [27-36].  
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Reduction of bacteriuria and pyuria by cranberry juice in postmenopausal women was 
studied in a double blind, placebo controlled clinical trial in 1994 [27]. 153 subjects were given 
300mL of either cranberry juice or placebo beverage daily for six months. The odds of 
bacteriuria and pyuria in cranberry group were 42% of that of the control group, demonstrating 
the efficacy of cranberry in reducing the two types of infections. In another randomized trial for 
150 women with previous UTIs [30], cranberry-lingonberry juice and Lactobacillus (a probiotic) 
drink’s effects in preventing UTIs were examined. During the first six months of the study, the 
cranberry- lingonberry group showed a much lower recurrence rate (16%) compared to the 
Lactobacillus group (39%) and the control group (36%) (Figure 1.3). The results indicated 
cranberry is effective in preventing recurrent UTIs. Other clinical trials also suggested American 
cranberry’s inhibitive effects on UTIs among the elderly [32] and sexually active women [34].  
 
Figure 1.3 Cumulative rate of first recurrence of UTI during 12 month follow up in women 
receiving cranberry-lingonberry mixture for six months, Lactobacillus drink for 12 months, 
or no intervention [30] 
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1.3.2 Cranberry preventing UTIs: mechanisms 
There have been several hypotheses of how cranberry interacts with uropathogens to 
reduce infections. It was suggested that the acidity of urine, due to hippuric and benzoic acid 
contained in cranberry, could inhibit bacterial growth and thus prevent infections [37]. However, 
clinical trials showed that drinking cranberry juice could not [27] or could only transiently 
acidify the urine [38]. It was also proposed that the increase of anti- inflammatory compound 
level (typically salicylic acid) associated with cranberry juice consumption was a possible 
mechanism of cranberry’s anti- infection effects [39]. But this theory could not explain why 
consumption of many other natural products does not prevent UTIs, since salicylic acid is a 
common compound contained in many plants.  
The current understanding on cranberry’s beneficial effects in the urinary tract are 
focused on the fact that cranberry prevents bacterial adhesion [40-43]. In recent years, a group of 
tannins called proanthocyanidins (PACs) extracted from cranberry have drawn much attention 
among researchers. PACs were first identified in 1998 as the anti-adhesion components in 
cranberry [40]. The structure of these PACs were elucidated in 2000 [44], where it was found 
that cranberry PACs have the A-type linkage in the molecular structure, which is unique to 
cranberry and has not been found in procyanidins or PACs from other fruits. The A-type linkage 
refers to the double bonds between the epicatehin/catechin units in PACs molecules (Figure 1.4), 
as opposed to B-type linkages which are single bonds. There could be one or more A-type 
linkage in a PAC molecule. While B-PACs, which are contained in many natural products 
including green tea, grape, and chocolate, do not demonstrate anti-adhesion effects [45], A-PACs 
showed the ability to inhibit adhesion of uropathogenic bacteria in vitro [46].  
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Figure 1.4 Molecular structure of A-PACs [44]. 
Although A-PACs are identified and widely recognized as the potential effective 
components in cranberry that reduce bacterial adhesion, it remains a question whether PACs are 
the only or major anti-adhesion components in cranberry, since some studies showed that 
cranberry juice had a higher anti-adhesion activity than A-PACs alone [47]. The mechanisms of 
how cranberry prevents uropathogenic bacteria from binding to host tissue are also still not clear. 
It has been shown that the molecular conformation [48] and agglutination ability [49] of E. coli 
P-fimbriae changed after incubation with cranberry juice; cranberry was also found to change the 
zeta potential of E. coli [50]. In addition, it has been shown that incubating with cranberry juice 
could significantly reduce the amount of biofilm formed by E. coli [47]. Although these studies 
demonstrated cranberry can change the surface properties and biofilm formation ability of E. coli, 
many of them were done with cranberry juice or A-PACs; the metabolism of cranberry 
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components is not thoroughly understood, and the anti-adhesion effects of cranberry metabolites 
remaining in urine need further investigation.  
This work will address cranberry’s effects on the surface properties and biofilm 
formation ability of uropathogenic bacteria after oral consumption. 
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Chapter 2: Oral Consumption of Cranberry Juice Cocktail 
Inhibits Molecular-Scale Adhesion of Clinical 
Uropathogenic Escherichia coli  
2.1 Abstract 
Cranberry juice cocktail (CJC) has been shown to inhibit the formation of biofilm by 
uropathogenic E. coli. In order to investigate whether the anti-adhesive components could reach 
the urinary tract after oral consumption of CJC, a volunteer was given 16 oz. of either water or 
CJC. Urine samples were collected at 0, 2, 4, 6, and 8 hours after consumption of a single dose. 
The ability of compounds in the urine to influence bacterial adhesion was tested for six clinical 
uropathogenic E. coli strains, including four P-fimbriated strains (B37, CFT073, BF1023, J96) 
and two strains not expressing P-fimbriae but exhibiting mannose-resistant hemagglutination 
(MRHA) (B73 and B78). A non-fimbriated strain, HB101, was used as a control. Atomic force 
microscopy (AFM) was used to measure the adhesion force between a silicon nitride probe and 
bacteria cells treated with urine samples. Within two hours after CJC consumption, bacteria of 
the clinical strains treated with the corresponding urine sample demonstrated lower adhesion 
forces than those treated with urine collected before CJC consumption. The adhesion forces 
continued decreasing with time after CJC consumption over the eight hour measurement period.  
The adhesion forces of bacteria after exposure to urine collected following water consumption 
did not change. HB101 showed low adhesion forces following both water and CJC consumption 
and these did not change over time. The AFM adhesion force measurements were consistent with 
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the results of a hemagglutination assay, confirming that oral consumption of CJC could acts 
against adhesion of uropathogenic E. coli cells. 
Key Words: Cranberry, anti-adhesion, urinary tract tinfections, Escherichia. coli  
2.2 Introduction 
Urinary tract infections (UTIs) are the most common community-required infections 
affecting the human body [1], with yearly costs estimated to be $1.6 billion in the U.S [1, 2]. The 
main UTI pathogen is E. coli,  which causes 90% of community-acquired UTIs and 30% of 
nosocomial UTIs [3, 4]. Infections are initiated when pathogenic bacteria attach to uroepithelial 
cells via the binding of bacterial adhesins to the receptors on the host cell membrane [5]. Typical 
adhesins of uropathogenic E. coli include type 1 fimbriae, P fimbriae, and X adhesins [5]. Type 1 
fimbriae-mediated adherence can be blocked by D-mannose, α-methylmannoside, and many 
other mannose analogs, and therefore this mechanism is termed mannose-sensitive adhesion [6]. 
The binding of P fimbriae and X adhesins to uroepithelial cells cannot be blocked by mannose or 
its analogs, and thus this mechanism is termed mannose-resistant adhesion [7, 8].  
UTIs are conventionally treated with antibiotics but there are concerns due to the 
development of antibiotic resistance and the problem of recurrent UTIs that affect some patients. 
Therefore, alternative therapies are drawing increasing interest among researchers. The 
American cranberry (Vaccinium macrocarpon) was shown to prevent UTIs in some studies [9-
11], but the underlying mechanisms have not been fully explored. A family of phytochemicals in 
cranberry, A-type proanthocyanidins (A-PACs), were identified as the anti-adhesive components 
[12]. The non-dialyzable material (NDM) in cranberries containing mainly A-PACs and some 
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unidentified molecules, has been used in some studies and  had anti-adhesive activity [13]. 
Incubation of P-fimbriated E. coli with 60 μg/mL A-PACs significantly decreased mannose 
resistant human red blood cell (HRBC) hemagglutination, and similar effects were observed 
when A-PAC solution was substituted with urine that was collected from volunteers who drank 
cranberry juice cocktail [14]. In our previous study using atomic force microscopy (AFM) to 
measure adhesion forces between P-fimbriated E. coli and a silicon nitride probe, the average 
adhesion forces decreased after 12 cultures in the presence of light CJC (from 1.60 ± 0.71 nN to 
0.56 ± 0.3 nN) or PACs (from1.60 ± 0.71 nN to 0.42 ± 0.2 nN), and the frequency distribution of 
adhesion forces shifted to lower values as the concentration of cranberry juice in the culture 
media increased [15, 16].  
Previous studies have not addressed whether cranberry juice compounds have molecular-
scale anti-adhesive activity after passing through the digestive system. Therefore, we 
investigated CJC’s effects on adhesion forces of clinical E. coli strains, including antibiotic 
resistant strains that were isolated from patients with cystitis or acute pyelonephritis. Using direct 
adhesion force measurements with AFM, the effects of cranberry components or metabolites 
remaining in urine on the adhesion of E. coli were investigated. The adhesion forces measured 
with AFM were correlated to the results of a macroscopic assay, namely the agglutination of red 
blood cells exposed to specific E. coli agglutinins. To our knowledge, this is the first molecular-
scale study to confirm the existence of anti-adhesive molecules in urine after oral consumption of 
CJC. 
16 
 
2.3 Materials and Methods 
2.3.1 Urine samples 
Urine samples had been collected for other IRB-approved research studies at Rutgers 
University.  The samples sent to Worcester Polytechnic Institute (WPI) were de- identified, and 
no personal information was provided.   A random, crossover design was applied, with a single 
volunteer.  The volunteer was a healthy Caucasian male, aged 42. He drank 16 oz. (240 mL) of 
commercial cranberry juice cocktail (CJC) or water. After consuming the single dose, urine was 
collected at intervals of 0, 2, 4, 6, and 8 hours. Samples were immediately frozen and shipped to 
WPI, where they were stored at -20 ºC. Urine samples were later thawed and filtered through 0.8 
μm (Pall Corp., East Hills, NY) and 0.2 μm (VWR InternationalTM, West Chester, PA) 
polyethersulfone syringe filters, sequentially. 
2.3.2 Bacteria cultures  
Six E. coli clinical strains that cause acute pyelonephritis or cystitis were selected, and a 
lab strain with no fimbriae was used as a control. The clinical strains possess a variety of surface 
properties, adhesin types, and antibiotic sensitivities (Table 2.1). To study different types of 
adhesins we chose two strains from each of the most common subgroups: i) strains that 
demonstrate mannose hemagglutination (MRHA) but no P-fimbriae (B73, B78); ii) strains that 
express P-fimbriae from class II (B37, CFT073); and iii) strains that express P-fimbriae from 
class III (BF1023, J96).  
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Table 2.1 Summary of properties and sources of 7 E.coli strains studied. All isolates also express 
type 1 fimbriae except HB101.  
Strain Fimbriae/Info Source 
B73 No P-fimbriae but exhibits MRHA 
(may be Dr adhesins); trimethoprin-
sulfamethoxazole resistant 
Dr. James Johnson, VA Medical Ctr, 
Minneapolis, MN; isolated from female 
with cystitis [39] 
B78 No P-fimbriae but exhibits MRHA 
(may be Dr adhesins); 
ampicillin/sulfamethoxazole 
intermediate resistance 
Dr. James Johnson, VA Medical Ctr, 
Minneapolis, MN; isolated from female 
with cystitis [39] 
B37 P-fimbriae from class II, 
ampicillin/sulfamethoxazole 
intermediate resistance 
Dr. James Johnson, VA Medical Ctr, 
Minneapolis, MN; isolated from female 
with cystitis [39] 
CFT073[WAM 
2267] 
Type P-fimbriae from class II  ATCC 700928; isolated from blood and 
urine of a woman with AP 
BF1023 P-fimbriae, class I and class III ATCC 700414; isolated  from a female 
patient with cystitis [40] 
J96 P-fimbriae, class I and class III ATCC 700336; isolated from a patient 
with pyelonephritis; [41, 42] 
HB101 Non-fimbriated, lab strain (non-
pathogenic control) 
ATCC 33694 
 
Bacteria were cultured at 37 ºC in colonizing factor antigen (CFA) media. CFA media is 
composed of 1% (w/v) casamino acids (BactoTM, Sparks, MD 21152), 0.078% (w/v) yeast 
extract (BactoTM, Sparks, MD 21152), 0.4mM MgSO4 (Sigma-Aldrich), 0.04mM MnCl2 (Sigma-
Aldrich) in ultrapure water, and the pH was adjusted to 7.4 using sodium hydroxide (Sigma-
Aldrich). For culture plates, 2% agar (BactoTM, Sparks, MD 21152) was added to the media. 
Bacteria were grown overnight and harvested at late exponential phase, when the absorbance of 
the culture was 0.9-1.1 at a wavelength of 600 nm, measured with a spectrophotometer (Thermo 
Spectronic, Rochester, NY). Bacteria were washed three times with ultrapure water by 
centrifuging the solution at 2000 g and removing the supernatant.  
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2.3.3 AFM adhesion force measurements 
Bacteria were attached to glass slides before AFM experiments [17, 18]. Glass slides 
were treated with 3:1 (vol/vol) HCl/HNO3 solution (Fisher Chemical, Fair Lawn, NJ) for 45 
minutes and rinsed with ultrapure water. Slides were soaked with 7:3 (vol/vol) H2SO4/H2O2 
solution (Fisher Chemical) and rinsed with ultrapure water. The acid cleaned glass slides were 
stored at 4 oC in ultrapure water until use. Glass slides were functionalized with an amine group 
to facilitate bacterial attachment.  Glass slides were treated with ethanol (Sigma-Aldrich), 
methanol (Sigma-Aldrich), and then immersed in solution of 35% 3-
aminopropyltrimethoxysilane (Sigma-Aldrich) in methanol for 15 minutes followed by rinsing 
with ultrapure water. A 300 μL solution of 100 mM 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) (Pierce, Rockford, IL) was added to the washed E. coli cells and incubated 
at 37 oC for 10 minutes with rotation at 18 rpm, followed by addition of a 600 μL solution of 40 
mM N-hydroxysulfosuccinimide (NHS) (Pierce, Rockford, IL) solution and incubation at 37 oC 
for 10 minutes with rotation at 18 rpm. Bacteria solution incubated with EDC and NHS was 
added to the 3-aminopropyltrimethoxysilane -treated glass slides and agitated at 70 rpm for 4 
hours to allow bacteria to bind onto the slides. Viability and morphology of bacteria cells were 
maintained during the binding process [19].  
AFM adhesion force measurements were performed using a Dimension 3100 instrument 
with Nanoscope IIIa controller (Veeco Metrology, Santa Barbara, CA). Silicon nitride 
cantilevers with spring constants of 0.12 ± 0.02 N/m (DNPS, Veeco Metrology) were used to 
acquire images and force data. Before experiments, the cantilevers were cleaned by immersing in 
ethanol and exposing to ultraviolet light. All the measurements were done with the slides and 
cantilevers immersed in the same urine sample that the slides were treated with, in order to 
19 
 
mimic the physiological environment. From each slide, five bacteria were probed, and ten force 
measurements were made in the center of each bacterium. Force data were exported in ASCII 
format and analyzed as described previously [20] to acquire adhesion force-separation distance 
data. During the portion of the force profile where the AFM tip retracts from the bacterial surface, 
adhesion peaks are often observed.  On each retraction curve the peaks represent the moment 
when the AFM probe pulls off from the cell surface, and the values of the forces at the peaks are 
defined as adhesion forces between the probe and the cell surface. 
2.3.5 Human Red Blood Cell (HRBC) agglutination assay   
Whole blood (type O positive) acquired from a volunteer was stored with EDTA at 4 ºC. 
Before the agglutination experiment, the red blood cells were separated from whole blood by 
centrifugation at 200 g for 10 minutes, in order to remove the platelets and plasma. The resulting 
red blood cells were suspended in phosphate buffered saline (PBS) and washed three times. After 
each wash the supernatant was removed and the remaining cells were resuspended in PBS. The 
concentration of red blood cells in the suspension was measured using a hemacytometer 
(Hausser Scientific, Horsham, PA). The suspension was diluted with urine to a concentration of 
107 red blood cells/ mL. The urine samples used in the HRBC agglutination assay were those 
collected at intervals of 0-2 hours or 6-8 hours after water or CJC consumption, as described 
above. 
E. coli cells harvested at late exponential stage were diluted in urine to 109 cells/ mL. Red 
blood cells and bacteria were incubated separately in urine at 37 oC for three hours. Then the two 
were co-incubated for 90 minutes to allow agglutination. The number of bacteria that attached to 
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red blood cells was counted under a light microscope (Nikon Eclipse E400). For each urine 
sample, the number of attached E. coli bacteria was counted on 20 red blood cells.  
2.4 Results 
2.4.1 Adhesion force measurements and analysis   
When the clinical E. coli strains were incubated with the background urine sample (urine 
collected just before water or CJC consumption), this resulted typically in adhesion forces above 
1nN, which varied somewhat depending on the strain (Table 2.2). E. coli BF1023 had the highest 
background adhesion force of 1.68 ± 1.01 nN, while B73, B37, B78, CFT073 and J96 had 
background adhesion forces between 1.00 and 1.3 nN. HB101, the lab strain that has no fimbriae, 
showed the lowest background adhesion force of 0.40 ± 0.26 nN.  
When cultured with urine samples collected at different time intervals following CJC 
consumption, all the clinical E. coli strains demonstrated decreasing adhesion forces with time 
after initial CJC consumption (Figure 2.1). The adhesion forces of clinical bacteria cultured with  
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Table 2.2 Mean adhesion force between a silicon nitride AFM probe and bacteria cells and standard deviation (SD) measured after 
treatment with urine samples collected before (background) and after consumption of 16 oz water or cranberry juice (CJC) 
strain Urine Sample Treatment 
Mean Adhesion Force ± SD (nN) 
background 0-2hr 2-4hr 4-6hr 6-8hr 
B73 
Water 
1.30±0.77 
1.42±0.63 1.15±0.61 1.13±0.50 1.26±0.77 
CJC 0.52±0.31*'  0.42±0.25*'  0.30±0.17*'  0.29±0.25*'  
B78 
Water 
1.30±0.86 
1.37±0.72 1.33±0.88 1.44±0.91 1.33±0.82 
CJC 0.98±0.73*'  0.73±0.45*'  0.66±0.35*'  0.49±0.24*'  
B37 
Water 
1.07±0.41 
0.84±0.49* 0.75±0.40* 1.04±0.62 0.96±0.42 
CJC 0.69±0.30* 0.61±0.32* 0.47±0.21*'  0.47±0.22*'  
CFT073 
Water 
1.12±0.75 
0.99±0.70 1.02±0.60 0.89±0.50 0.82±0.47 
CJC 0.77±0.50*'  0.47±0.36*'  0.44±0.27*'  0.38±0.18*'  
BF1023 
Water 
1.68±1.01 
1.61±1.1 1.82±1.20 1.75±1.21 1.64±0.94 
CJC 0.86±0.44*'  0.72±0.34*'  0.45±0.25*'  0.29±0.12*'  
J96 
Water 
1.25±0.78 
1.29±0.59 1.29±0.62 1.35±0.75 1.30±0.42 
CJC 0.88±0.52*'  0.48±0.26*'  0.49±0.19*'  0.38±0.33*'  
HB101 
Water 
0.40±0.26 
0.42±0.31 0.45±0.0.32 0.43±0.36 0.46±0.37 
CJC 0.41±0.22 0.35±027 0.43±0.46 0.41±0.22 
 
*Statistically significant difference compared to background (p<0.05).  
' Statistically significant difference compared to treatment with urine sample collected at the same time point after water consumption 
(p>0.05). 
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 urine collected 0-2 hours after drinking CJC decreased to below 1nN for all the clinical strains. 
Adhesion forces continued to decrease for 8 hours, when the adhesion forces became as low as 
0.2 - 0.5 nN. The control strain, HB101, did not show significant changes in the adhesion forces 
during the 8 hours following CJC consumption.  
 
Figure 2.1  Adhesion forces of E.coli cells measured by AFM after incubating with urine.  
Water consumption did not affect the adhesion forces of the clinical and lab strains, with 
the exception of B37 (Table 2.2). Following water consumption, B37 showed an adhesion force 
of 0.84 ± 0.49 nN at 0 – 2 hours and 0.75 ± 0.40 nN at 2 – 4 hours, which were significantly 
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different from the background; but those adhesion forces were still higher than adhesion forces 
measured after CJC consumption at the same time intervals. For B73, B78, CFT073, BF1023 and 
J96, the adhesion forces stayed above 1nN or slightly below 1nN with no significant differences 
from the background. The adhesion forces of HB101 remained between 0.3 - 0.5 nN with no 
significant differences from the background.  
The ANOVA tests showed that for all the clinical strains, adhesion forces after CJC 
consumption were significantly lower than the background adhesion force levels (Table 2.2). The 
adhesion forces measured after CJC consumption also were lower compared to those measured 
at the same time intervals after water consumption. B37 showed higher adhesion forces with 
treatment of urine collected after water consumption, but within 4 hours after consumption, the 
adhesion forces after water consumption were only slightly higher than those after CJC 
consumption, and the difference between the two was not statistically different. After 4 hours the 
adhesion forces after water consumption increased and became significantly higher than the CJC 
group. For the majority of clinical strains, namely B73, B78, CFT073, BF1023 and J96, the 
difference of adhesion forces between CJC and water was statistically significant at each time 
interval, with adhesion forces after water consumption higher than CJC consumption.  
2.4.2 Human Red blood cell (HRBC) agglutination assay 
Co-culturing clinical strains with urine samples collected 6-8 hours after CJC 
consumption (CJC (6-8)) resulted in high bacteria cell retention on red blood cells (RBC) (Figure 
2.2). The mean number of attached E. coli cells per RBC was above six with two strains having 
especially high retention (11.35 bacteria/ RBC for CFT073 and 11.85 bacteria/ RBC for BF1023). 
24 
 
The retention after CJC (6-8) culturing was significantly lower, being typically below two 
bacteria/ RBC. 
The control strain HB101 demonstrated low retention to RBCs after culturing in either 
water (6-8) (0.15 bacteria/ RBC) or CJC (6-8) (0.35 bacteria/ RBC), and there was no 
statistically significant difference between water and CJC.  
 
Figure 2.2 Attachment of E. coli cells to red blood cells (RBC). 
2.5 Discussion 
2.5.1 Adhesion forces of E. coli 
Antibiotic resistance has been a major problem in the treatment of bacterial infections. 
CJC is a promising preventive therapy for UTIs since it works as an anti-adhesive instead of a 
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bactericide, and thus does not induce the development of antibiotic resistance. In this study, three 
antibiotic resistant strains isolated from female patients with cystitis were selected to investigate 
CJC’s effects on these bacteria (Table 1). All of the antibiotic resistant strains showed little 
change in adhesion forces after water consumption compared to a significant decrease after CJC 
consumption, indicating that cranberry juice is effective in preventing non-specific adhesion of 
these antibiotic resistant E. coli strains.  
For many years, it has been recognized that uropathogenic E. coli strains typically 
demonstrate mannose-resistant adhesion in mannose-resistant hemagglutination (MRHA) 
experiments [21-23]. While many phytochemicals in other fruits can inhibit mannose-sensitive 
adhesion, cranberry is one of the only fruits found to inhibit mannose-resistant adhesion [24, 25]. 
Therefore, it is important to investigate the adhesive properties of uropathogenic E. coli strains 
that demonstrate MRHA, especially how oral consumption of cranberry juice affects the 
adhesion of these strains in a simulated physiological environment (urine collected from a 
volunteer after CJC consumption). Therefore, strains used in this study are from two MRHA 
positive subcategories.  B37, CFT073, BF1023, and J96 have P-fimbriae.  Strains B73 and B78 
do not have P-fimbriae, but exhibit MRHA. 
P-fimbriae are considered the dominant virulence factors in upper UTIs [26]. They were 
named after the P blood group antigens (a family of oligosaccharides with the Galα(14)Galβ  
moiety) that they bind to. Although Galα(14)Galβ containing receptors are not abundant in the 
membrane of shed human epithelial cells [27], they are dominant in human renal cell membranes 
[28]. P-fimbriae adhere to epithelial cells in multiple tissues in upper urinary tract [29], 
explaining the high probability of P-fimbriae-mediated upper UTIs, such as acute pyelonephritis. 
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P-fimbriae also adhere to the epithelial and muscular layers of the bladder [30], indicating their 
involvement in lower UTIs. In addition, human polymorphonuclear leukocytes (hPMNLs) in 
blood only have trace amounts of glycolipids containing Galα(14)Galβ [31, 32], rendering a 
poor binding of hPMNLs with pathogenic P-fimbriated bacteria and thus the killing of these 
bacteria. We showed a significant decrease in adhesion of P-fimbriated strains (B37, CFT073, 
BF1023, and J96) after incubation with urine samples that were collected after CJC consumption, 
compared to the non-fimbriated strain HB101 which demonstrated low adhesion forces 
throughout the 8 hours after CJC consumption. These results indicated that the anti-adhesive 
components or metabolites of CJC remaining in urine have an inhibitive effect on uropathogenic 
E. coli adhesion.  
The adhesins of the other two MRHA positive strains, B73 and B78, have not been 
clearly identified yet, they may be Dr adhesins which belong to the X adhesin family. The X 
adhesin family consists of Dr adhesins, S fimbriae, F1C fimbriae, M adhesins, G fimbriae, and 
other unidentified X adhesins [5]. The Dr adhesins differ from fimbriae because they are not 
distinct filaments. They can exist as a fine mesh, a coil- like structure, or a filamentous capsular 
coating [33]. The receptors for Dr adhesins are the Dr blood group antigens located on the decay-
accelerating factor, a group of cell membrane proteins regulating the complement cascade [34]. 
The binding site of Dr adhesins in the urinary tract include the renal interstitium, Bowmans 
capsule, tubular basement membrane, ureteral transitional epithelial cells, and exfoliated cells in 
urine [34]. 
B73 and B78 were isolated from cystitis patients, and the Dr adhesin family constitutes 
78% of X adhesin strains among cystitis patients isolates [33]. Therefore, it is likely that B73 and 
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B78 have Dr adhesins. Our results showed that similar to P-fimbriated strains, B73 and B78 
showed decreased adhesion forces after being treated with urine from the volunteer who 
consumed CJC. Although the molecular binding mechanisms of Dr adhesin and P-fimbriae are 
different in the urinary tract, CJC can inhibit the adhesion of both, which could be a result of 
decreased non-specific adhesion induced by CJC metabolites remaining in urine. Using contact 
angle measurements, a previous study [35] showed that cranberry juice could induce a decrease 
in non-specific adhesion between P-fimbriated E. coli and uroepithelial cells. Since non-specific 
adhesive interactions, including van der Waals forces, electrostatic forces, and hydrophobic 
interactions, do not involve the specific adhesin-receptor binding, it is likely that CJC 
metabolites influence the strains without P-fimbriae in the similar way they affect P-fimbriated 
strains by diminishing non-specific interactions [36, 37]. It is also possible that CJC metabolites 
can change the amount and conformation of E. coli surface macromolecules and thus the 
adhesion activity [15, 38]. We showed previously that cranberry juice reduced the equilibrium 
length of E. coli P-fimbriae from ~148 nm to ~48 nm [15], suggesting the compressing of 
surface macromolecules on E. coli could be a mechanism of decreased adhesion, which could 
explain the non-specific adhesion decrease after CJC consumption in both P-fimbriated and non 
P-fimbriated E. coli strains.  
2.5.2 RBC agglutination assay 
While the adhesion forces measured with a silicon nitride AFM probe represent the non-
specific adhesion of E. coli cell surfaces including van der Waals forces, electrostatic and 
hydrophobic interactions, biological interactions also include specific types of adhesion, such as 
receptor- ligand bonds. AFM adhesion force measurements represent non-specific adhesion 
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between the silicon nitride AFM probe and the bacterial surfaces, whereas the RBC agglutination 
assay represents overall interaction between bacteria cells and human cells, which contains both 
non-specific and specific adhesion.  
Compared to the control strain HB101, all the clinical strains demonstrated high retention 
to RBCs after co-culturing with the urine sample collected 6-8 hours after water consumption 
(water (6-8)) (Figure 2), which can be explained by the fact that HB101 does not have any 
adhesins. When co-cultured with the urine sample collected 6-8 hours after CJC consumption 
(CJC (6-8)), the retention of HB101 did not change compared to water (6-8). These results 
suggest that CJC metabolites remaining in urine can inhibit overall adhesion of uropathogenic E. 
coli.  
In conclusion, by incubating uropathogenic E. coli with urine collected after water or CJC 
consumption, and measuring the resulting change of adhesion force between E. coli cell surface 
and an AFM probe, we were able to demonstrate that the anti-adhesive components in CJC could 
reach the urinary tract, and these components were active in preventing non-specific adhesion. 
We also confirmed that CJC components remaining in urine played a role in inhibiting specific 
adhesion of E. coli by means of HRBC agglutination assay. 
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Chapter 3: A Pilot Clinical Study of Cranberry Juice 
Cocktail for Preventing Biofilm Formation of 
Uropathogenic Bacteria 
 
3.1 Abstract 
A double-blind, placebo-controlled pilot clinical trial of the effect of cranberry juice 
cocktail (CJC) consumption on biofilm formation was conducted in 11 healthy women between 
the ages of 18 and 27. A single dose of 16 oz. of CJC or a placebo beverage was given to the 
volunteers, and urine samples were collected in the following 48 hours. Bacteria (E. coli B37, 
CFT073, BF1023, HB101, and S. aureus ATCC43866) were cultured in the urine samples 
supplemented with media and the amount of biofilm formed was measured using a crystal violet 
absorbance assay in a 96-well plate. In the urine of volunteers who had consumed CJC, b iofilm 
formation was inhibited within 24 hours after CJC consumption, and biofilm formation started to 
increase after 48 hours by 49-67%. S. aureus showed the least biofilm formation after incubation 
with post-CJC urine. The results indicate that drinking CJC can be an effective preventive 
measure for bacterial adhesion and biofilm formation in healthy women. The anti-biofilm 
activity peaks between 24 and 48 hours after drinking CJC.  
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3.2 Introduction 
Considered to be one of the most common bacterial infec tions, urinary tract infections 
(UTIs) account for nearly 7 million physician visits per year with estimated costs of $1.6 billion 
in the U.S [1]. Women are much more prone to UTIs compared to men, and by the age of 24, a 
third of women are estimated to have had at least one physician-diagnosed UTI [2].  
Alternative therapies for UTIs have drawn increasing interest due to concern of antibiotic 
resistant bacteria. The American cranberry (Vacciniumm macrocarpon) is a potential therapeutic 
for UTIs, and several clinical studies have shown that consumption of cranberry can help prevent 
UTIs among elderly people [3], elderly women [4], and sexually active women with previous 
UTIs [5]. Cranberry products are consumed by many healthy women as a preventive measure, 
research is needed to elucidate how oral consumption of cranberry affects the activity of 
uropathogenic bacteria.  
Cranberry juice has been shown to reduce the surface adhesion ability of E. coli 
measured by atomic force microscopy [6], it was also shown to inhibit the attachment of E. coli 
to human uroepithelial cells, red blood cells, and resin beads coated with receptors that bind to P-
fimbriae, the filaments on E. coli cell surface that facilitate adhesion. [6-8]. But whether drinking 
cranberry juice helps prevent UTIs by inhibiting biofilm formation in the urinary tract is still 
unclear. As the first step of bacterial infection, biofilm formation is of significant interest to 
researchers [9]. Therefore, the present study used a biofilm formation assay to determine the 
efficacy of cranberry juice cocktail (CJC) to reduce biofilm formation in the urine of healthy 
women. 
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3.3 Participants and Methods 
3.3.1 Study subjects 
After advertising through email and fliers, female students from Worcester Polytechnic 
Institute (MA) between the ages of 18 and 27 were screened for enrollment in this trial. 
Volunteers were tested for UTIs using a dipstick test, and those with UTIs were excluded from 
the study and were referred for treatment at the University Health Services. Twenty volunteers 
qualified, and 16 oz of CJC and 16 oz of placebo (Ocean Spray) were provided to each them. 
Each volunteer drank CJC, followed by placebo at least one week after CJC consumption to 
avoid interference between the two treatments. Volunteers were asked not to consume any other 
berries or juices during this time, in order to exclude the intervention of metabolites possibly 
similar to cranberry metabolites. The study was double blind (volunteers and researchers). Urine 
samples were collected at 0, 2, 4, and 8 hours after CJC or placebo consumption, with the 0 hour 
sample serving as a baseline. Four volunteers dropped out because they admitted to not drinking 
the correct amount of beverage or did not drink the entire beverage at a single time, and five 
volunteers were excluded since they provided an insufficient amount of urine or did not supply 
the correct time points. 
3.3.2 Biofilm formation assay 
Urine samples were centrifuged at 2000g to remove epithelial cells and filtered using 0.8 
μm and 0.25 μm polyethersulfone syringe filters (VWR InternationalTM, West Chester, PA) 
sequentially to remove bacteria or other particles. Bacterial samples tested were three clinical E. 
coli isolates (CFT073, B37, and BF1023), a non-pathogenic lab strain of E. coli with no fimbriae 
(HB101), and a Staphylococcus aureus strain (ATCC 43866). Bacteria were cultured in LB 
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media (35g/L, Sigma-Aldrich, St. Louis, MO), harvested at late exponential stage, which 
corresponded to an absorbance of 0.9-1.1 measured at a wavelength of 600nm using a 
spectrophotometer (Thermo Spectronic, Rochester, NY), and then mixed with urine samples at a 
ratio of 1: 1. The mixed suspension was transferred into a 96-well PVC microtiter plate and 
incubated at 37 ºC. After six hours of incubation, 20 μL of crystal violet was added to stain 
bacteria cells for 10 minutes, and the microtiter plate was washed three times with ultrapure 
water to remove planktonic bacteria. The biofilm was extracted using 400 μL extracting agent 
(20% acetone in ethanol v/v). The absorbance of the extract was measured at the wavelength of 
600 nm, as the indicator of the amount of biofilm [9]. Each urine sample was tested in three 
repeats. 
3.3.4 Data analysis 
For each volunteer, the post-CJC and post-placebo urine samples’ effects on biofilm 
formation were compared using the Student’s t-test. The difference of biofilm amount across all 
11 volunteers between post-CJC and post-placebo urine were also tested using the Student’s t-
test.  The significance level of the test was 0.05, and the time point zero samples were used as a 
baseline. 
3.4 Results 
3.4.1 Individual responses to CJC 
For a given strain of bacteria, an individual was considered to be responsive to CJC if the 
difference in biofilm formation between post-CJC urine and post-placebo urine was significant 
(P<0.05).  The results showed that within 24 hours after drinking CJC, the number of volunteers 
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who showed a reduced biofilm formation increased, and this trend was similar in all the strains 
tested (Table 3.1). The response at 48 hours after drinking CJC differed among the strains. E. 
coli BF1023 and S. aureus showed an increased number of responding volunteers at 48 hours 
compared to 24 hours, whereas for the other strains, the numbers of these volunteers stayed 
unchanged or decreased (Table 3.1). The degree of biofilm reduction also varied with bacterial 
strain; S. aureus had the most significant biofilm decrease, whereas E. coli BF1023 showed very 
little change after treatment with post-CJC urine. These variations may result from the different 
susceptibility of each strain to CJC treatment, and variant surface properties such as adhesin type 
and density. 
Table 3.1. Number of volunteers that showed a significant difference between CJC and 
placebo (total number of volunteers is 11) . Significant level 0.05 in Student’s test. 
Strain 
# of volunteers showing difference between CJC and placebo 
0hr 2hr 8hr 24hr 48hr 
E. coli B37 0 4 4 8 2 
E. coli CFT073 0 3 5 5 5 
E. coli BF1023 0 1 2 3 4 
S.aureus (ATCC43866) 0 5 6 6 9 
E. coli HB101 0 1 3 4 2 
 
3.4.2 Biofilm formation affected by CJC consumption 
For the biofilm amount measured at each time point, the difference between the CJC 
group and the placebo group was determined using the Student’s t-test (Table 3.2). For all the 
strains except E. coli HB101, biofilm formation decreased within 24 hours after CJC 
consumption and slightly increased between 24 and 48 hours after CJC consumption (Table 3.2). 
The amount of biofilm formed by non-pathogenic E. coli HB101 after culturing in post-CJC  
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Table 3.2. Amount of biofilm formed after culturing in urine samples collected from volunteers drinking CJC or placebo. 
Biofilm amount at hour 0 serves as baseline. 
strain Urine Sample Treatment 
Mean Absorbance at 600 nm ± SD  
0hr 2hr 8hr 24hr 48hr 
E. coli B37 
Placebo 0.000±0.101 
0.000±0.073 
0.021±0.193 0.030±0.170 0.157±0.410 0.213±0.427 
CJC -0.090±0.207 -0.121±0.136 -0.214±0.175* -0.090±0.254* 
E. coli CFT073 
Placebo 0.000±0.097 
0.000±0.060 
0.028±0.268 0.063±0.305 0.082±0.321 0.087±0.214 
CJC 0.000±0.216 -0.123±-0.182* -0.148±0.205* 0.041±0.227 
E. coli BF1023 
Placebo 0.000±0.029 
0.000±0.036 
0.011±0.058 -0.019±0.073 0.023±0.067 0.051±0.073 
CJC -0.020±0.067 -0.042±0.077 -0.045±0.058* -0.023±0.105* 
S.aureus 
(ATCC43866) 
Placebo 0.000±0.083 
0.000±0.066 
0.245±0.398 0.263±0.363 0.256±0.375 0.428±0.307 
CJC -0.057±0.222* -0.080±0.256* -0.274±0.212* -0.090±0.262* 
E. coli HB101 
Placebo 0.000±0.015 
0.000±0.009 
0.026±0.028 0.005±0.027 0.087±0.026 0.089±0.023 
CJC 0.142±0.033 -0.006±0.040 0.014±0.040 0.091±0.021 
 
* Statistically significant difference compared to the placebo group (p<0.05). 
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urine stayed unchanged over the 48 hours and did not show a difference from the biofilm amount 
formed after culturing in post-placebo urine. 
3.5 Discussion 
The first step of biofilm formation is bacterial adhesion, which is facilitated by adhesins 
on the surface of bacterial cells [10]. In order to develop cranberry juice products as a  preventive 
therapy for UTIs, we need more information on cranberry’s role in biofilm formation. According 
to the results of the biofilm formation assay, after the volunteers drank CJC, their urine collected 
could a decrease biofilm formation in bacteria strains that have adhesins (E. coli CFT073, E. coli 
B37, E. coli BF1023, and S. aureus), whereas the strain that does not have adhesins, E. coli 
HB101, was not affected (Table 2). These results indicate that drinking CJC prevents biofilm 
formation. The extent to which biofilm formation was inhibited could differ based on the adhesin 
density and type (E. coli B37, CFT073, and BF1023 have P-fimbriae, E. coli HB101 do not have 
fimbriae, and S. aureous have surface protein adhesins that are smaller than E. coli fimbriae). 
We also investigated the duration of CJC’s effects on biofilm formation after oral 
consumption. A previous study using human cell agglutination assay showed anti-adhesion 
activity of urine lasted for 10 hours after CJC consumption [7]. In our study, the number of 
volunteers whose urine showed an inhibitory effect on biofilm formation peaked between 8 and 
24 hours after CJC consumption, and decreased in some strains after 48 hours. This phenomenon 
could be a result of cranberry components or metabolites’ washing out from the body. This may 
explain why the amount of biofilm increased 48 hours after consumption of CJC. 
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In conclusion, our study demonstrated that cranberry juice is an effective method for 
preventing biolfilm formation in the urine of healthy women. Our study suggests that the 
inhibitory action of CJC is due to its ability to prevent bacterial adhesion and biofilm formation.  
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Chapter 4: Research Summary and Future Work 
4.1 Research Summary 
Throughout this project, we have sought to better understand how cranberry juice 
interacts with the adhesion activity of uropathogenic bacteria. In particular, we have made 
emphasis on how the oral consumption of cranberry juice cocktail (CJC) induces anti-adhesion 
effects in urine. Two mechanisms of cranberry’s effects on uropathogenic bacteria were studied, 
namely surface adhesion and biofilm formation.  
In Chapter 2, we investigated the effects of oral consumption of cranberry juice cocktail 
(CJC) on the surface adhesion forces of uropathogenic E. coli that were isolated from UTI 
patients. Our results showed that urine collected after CJC consumption decreased the non-
specific adhesion forces of uropathogenic E. coli measured by AFM, as well as the specific 
adhesion measured in a human red blood cell (HBRC) assay. 
In Chapter 3, we evaluated the biofilm formation of uropathogenic bacteria affected by 
consumption of CJC and the duration of CJC’s effects. We determined that biofilm formation of 
uropathogenic bacteria is reduced by urine collected after CJC consumption, and the inhibitory 
effects of CJC lasts 24-48 hours after consumption. 
4.2 Future Work 
It is important to understand how cranberry affects the interaction between bacteria and 
epithelial cells lining the urinary tract. To extend our work on surface adhesion forces of 
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uropathogenic E. coli to the investigation of E. coli-uroepithelium adhesion, we started 
collaborating with Dr. Amy Howell from Rutgers University in NJ, in an attempt to measure the 
adhesion forces between E. coli and uroepithelial cells.  
Dr. Amy Howell provided us with urine samples that were collected from volunteers who 
drank CJC or placebo. The time points of sample collection were 0, 2, 4, and 6 hours after 
consumption. To bind bacteria cells to the AFM probe, the probe was coated with ply-L- lysine 
(PLL) by immersing in PLL for 30 minutes. After drying in air for 10 minutes, the probe was 
immersed in a concentrated bacteria suspension for 10 minutes to allow bacteria to bind on the 
probe. The success of binding was confirmed using scanning electronic microscopy (SEM). We 
have maintained a human uroepithelial cell culture, and the adhesion forces between epithelial 
cells and bacteria were measured using the same technique we used to measure the bare probe-
bacteria adhesion. Using the same force data, the adhesion energy was also calculated by 
integrating force with separation distance using the MFP3D AFM software (detailed method and 
program script in the appendage). We have acquired some preliminary data of the bacteria-
uroepithelium adhesion forces using urine samples from one volunteer, as shown in Figure 4.1.  E. 
coli CFT073 is a strain we used in the AFM probe-bacteria adhesion measuring experiment, and 
it showed decreasing adhesion force with time after CJC consumption. However, the adhesion 
force between E. coli CFT073 and uroepithelial cells did not show a similar trend as we expected. 
To further investigate the adhesion, we calculated the adhesion energy using the force data. The 
result did not show a trend either (Figure 4.1). Similar results were acquired in experiments using 
S. aureus, where post-CJC did neither cause lower adhesion force or energy compared to post-
placebo urine, or adhesion force or energy decreasing with time after CJC consumption. There 
may be multiple factors that caused the unexpected results. First, the surface of uroepithelial cells 
44 
 
was highly heterogeneous. Even though in each experiment, we took force curves at multiple 
locations on each cell and multiple cells were measured, the surface property variation might be 
still too large to be overcome by the number of measurements we did. Second, the bacteria lawn 
coated on the AFM probes may vary from one experiment to another. With the dipping method  
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Figure 4.1 Adhesion force and energy between uroepithelial cells and bacteria (Volunteer 1) 
45 
 
 we used to coat AFM probes, it is impossible to control the amount of bacteria attaching to the 
probe. When more bacteria are attached to the probe, the interaction between the probe and 
uroepithelial cells is stronger, and vice versa. Therefore, the accuracy of the measurements was 
impaired by the difference in the bacteria coating.  
To overcome these artifacts, measurements could be done on more locations on epithelial 
cells to acquire a large enough sample size; or we could develop techniques to mount single 
bacteria cell onto AFM probes. If the accuracy could not be improved largely enough by these 
measures, we may pursue other assays to characterize interaction between uroepithelial cells and 
bacteria. 
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Appendage: Igor Script for Adhesion Energy Calculating 
#pragma rtGlobals=1  // Use modern global access method. 
#include ":AsylumResearch:Code3D:Initialization" 
#include <ProcedureBrowser> 
 
 //Finding the integral of force curves, verision 2, 9-14-2010 
 // For Igor Pro 6.20, MFP3D 090909+0825 
  
 //Written by Anne Murdaugh (amurdaugh@gmail.com) 
  
 //This code is still a little clunky when it comes to displaying and saving data.     
 // Got questions or improvements?  Feel free to contact me at the email addy above.  
  
 // Updates from v1:   
 // Integral curves are now found between the zero intercept and the last point on the curve.   
 // It automatically opens tables now. 
 // Data is saved as a .txt file rather than as igor waves.  
  
 //To use this protocol to find the integral: 
 // 1.  Select the force curves of interest.  Make sure you're plotting force vs. Zsnsr  
 // 2.  Place the cursors on the starting and ending points.   
 // 3.  In the Command line (that box titled "Untitled") type SetFilepath ("the name of the file 
folder containing the force curves") 
 //      Usually that folder is named something like "X100827" unless you specified a different 
save directory.  Just look on the master force panel if you're  
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 //      not sure. 
 // 4.   In the Command line type  FindArea ("prefix",j,k,"results")  
 //  "prefix" - the prefix to your file names.  Default is "Image".  Don't include the 
numbers that go with all these files 
 //  j - the first curve number to be analyzed; leave off the extra zeros (ie, 15, not 0015)  
//   k - the last curve number to be analyzed 
//  "results"  - the name to save your data to 
 
//  If you get a bunch of blanks or 0s, check to see that you're using Force vs. Zsnsr.  Also check 
and make sure the curves you told it to analyze are 
// displayed on the Force Review graph.   
 
//****************************************************************************
***************************************************************** 
 
Function SetFilepath (input1) 
  
  String input1        //The directory name where the force curves are 
kept 
 
  string /g directory = input1  //makes directory a global variable 
   
  SVAR gdirectory = directory  //Pulling up globla variable directory 
  String Filepath = "root:ForceCurves:Display:Subfolders:"+gdirectory 
 //creating needed path name 
  SetDataFolder Filepath   //Setting path 
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End  
 
//****************************************************************************
**************************************************************** 
 
Function FindArea (prefix,j,k,results) 
 
 String prefix    //The first part of the file name, ie Image 
 Variable j    //First file number 
 Variable k    //Last file number 
 String results    // Name for the results file 
  
 Variable n    // internal counting variable 
 String filenumber   //File number part of file name, ie 0002 
 String suffix     // End part of filename, ie Force_Ret 
 String xsuffix    //End part of filename for X axis, ie Zsnsr_Ret 
 String filename   // Total filename put together, y axis 
 String xfilename   // Total filename for x axis 
 Variable x1 
 Variable x2 
 
  
// Force curves have the name structure Image0000Force_Ext.  We need to increment the 
middle part (0000), and get the area 
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// under the curve.  Yes, that's an integral.. I know.  Just trust me here.  
 
 edit 
 Make /O /N=(k-j+1) energy   //Make the wave to hold the adhesion energy 
 Variable i     //Variable to increment adhesion energy 
wave 
  i = 0 
 
 suffix = "Force_Ret"   //This is added on to designate the retraction curve 
 xsuffix = "LVDT_Ret"   //This is added on to get us a Force vs Zsnsr 
curve 
 
 
 
// Force curve names have extra zeros, ie 0001 instead of 1.  We need to put in the right 
number. 
 
 String sigfig    //String to create the proper amount of zeros in 
filename 
  sigfig =""   // We'll determine that number in the for loop.  
  
  
   
// The for- loop follows.  For every curve between j and k it will: 
//   1.  Get the number of needed zeros (ie, 0001) 
//  2.  Put the whole filename together  (ie, Image0001Force_Ext)  
50 
 
//  3.  Find the area under the zero line between the cursors.  
 
 for (n = j; n <= k ; n += 1) 
 
   // 1.   Get the number of needed zeros   
    if (n<=9) 
     sigfig = "000"     
     elseif (10 <= n && n<= 99) 
      sigfig = "00" 
     elseif (100<= n && n <=999) 
      sigfig = "0" 
     else 
      sigfig = ""  
    endif   
    
   //2. Create the filename 
    filenumber = num2str (n)      
    filename =prefix+sigfig+filenumber+suffix 
    xfilename =prefix+sigfig+filenumber+xsuffix     
     
   //3. Find the area: 
     
    //3a) Find the last point on the curve: 
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    variable lastpoint  
    Wavestats /Q /W $filename 
     lastpoint = V_endRow 
    Duplicate /O $xfilename, tempcurve 
    Duplicate /O $filename, ytempcurve 
      
    x2 = tempcurve[lastpoint] 
    //print x2 
    
    //3b) Find the zero line 
    variable zeropoint 
     zeropoint = 0 
    variable m  
     
    for (m = 0; m<100; m+=1) 
     if (ytempcurve[m] > 0) 
      zeropoint = m 
     endif  
     endfor 
    
    x1 = tempcurve[zeropoint]  
    //print x1 
    
    
52 
 
    Wave adhesion = $filename  //This is just getting strings to 
turn into wave names. 
    Wave xadhesion = $xfilename 
     
    energy[i] = areaxy (xadhesion,adhesion,x2,x1)   // The magic 
command that actually finds the integral.  Hooray!  
     
    // Sanity Check.  Uncomment to check and make sure you're not 
getting the integral from - infinity to infinity 
    //variable energy_check 
    //energy_check = areaxy (xadhesion,adhesion,-inf,inf) 
    //print energy_check 
    //print "*******" 
    i +=1         
   //Whee! Increment!!! 
 killwaves tempcurve, ytempcurve   
  
 endfor  
  
  
 // This next part is just so that we can save our data in a unique file.  It too, could use 
some polishing.   
  
 Make /O /N=(k-j+1) $results      //Make the waves to hold the 
results 
 Duplicate /O energy, $results     
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 appendtoTable $results  
 Save /J $results       //Save the data! And 
the whales!  But mostly your data!   
 
 
End 
 
